{
  "symbol": "SRPT",
  "company": "Sarepta Therapeutics, Inc.",
  "generated_at": "2026-06-24T07:36:53.122Z",
  "event_count": 2,
  "events": [
    {
      "type": "scout_dossier",
      "ts": "2026-06-06T02:47:47.949Z",
      "summary": "Sarepta has cratered ~64% from its 52-week high of $43.92 to $15.75 following ELEVIDYS commercial deterioration tied to a regulatory crackdown on gene therapy dosing, though Q1 2026 showed unexpected EPS strength ($3.16 actual vs $0.99 est) driven by non-recurring items and stable legacy product revenues. The trigger was a cluster of 8 Form 4 filings from June 4 2026 — but every one represents RSU vesting grants (code A, at-the-money, zero cost), not open-market purchases. No director or officer bought stock with personal capital in the last 90 days. Options flow is strongly bearish (put/call ratio 7.35; new OTM put positioning at $17 strike). The forward P/E of 5.78x and ~12% FCF yield are compelling on paper, but without a genuine insider cash purchase signal — and against a backdrop of declining flagship drug sales and high leverage — there is no actionable mispricing + catalyst + edge combination.",
      "verdict": "no_anomaly",
      "confidence": 4,
      "tool_calls": 26,
      "walltime_min": 18,
      "debug_path": "dossiers/2026-06-06-SRPT.scout.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-06-05T03:42:07.456Z",
      "summary": "{\"symbol\":\"SRPT\",\"company\":\"Sarepta Therapeutics, Inc.\",\"investigation_summary\":\"Sarepta presents a deeply distressed picture: CEO retirement announced Feb 2026, Elevidys gene therapy sales declining following FDA boxed warning, VYONDYS/AMONDYS under potential ESSENCE trial withdrawal risk, and AAVrh74 platform on clinical hold. Q1 2026 earnings beat ($3.16 adj EPS vs $0.99 est) was driven by a ma",
      "verdict": "unparseable",
      "tool_calls": 21,
      "walltime_min": 13,
      "debug_path": "dossiers/2026-06-05-SRPT.scout.debug.json"
    }
  ],
  "lessons": [],
  "chart_signal": {
    "ticker": "SRPT",
    "call": "HOLD",
    "confidence": 1,
    "score": -2,
    "factors": {
      "below_200dma": "-2",
      "below_50dma": "-1",
      "momentum_down": "-1 (-10.6%)",
      "rsi_neutral": "0 (51.5)",
      "macd_above_signal": "+1",
      "recent_macd_bullish_cross": "+1 (5d ago)",
      "from_high": "0 (-29.4%)"
    },
    "summary": "HOLD (score -2) · 12-1 mom -10.6% · RSI 51.5 · below_both · -29.4% from high",
    "last_close": 17.26,
    "one_month_ago_close": 16.96,
    "twelve_month_ago_close": 18.98,
    "twelve_one_momentum_pct": -10.64,
    "rsi_14": 51.5,
    "ma_stack": "below_both",
    "from_period_high_pct": -29.41,
    "period_high": 24.45,
    "price_targets": {
      "bear": 5,
      "fair": 19.3,
      "bull": 38,
      "bear_return_pct": -71,
      "fair_return_pct": 11.8,
      "bull_return_pct": 120.2,
      "method": "street_targets ⨯ chart_floors",
      "street": {
        "target_low": 5,
        "target_mean": 22,
        "target_high": 38,
        "analyst_count": 23
      }
    },
    "generated_at": "2026-06-24T07:36:53.118Z"
  }
}